China Market Insider
How China’s Bioprocessing Industry Benefits from the Corona Crisis

A guest post by Henrik Bork*

Related Vendors

The Corona crisis has enabled the rapid rise of several Chinese bioprocessing companies. The sudden explosion in demand for cell cultures and other products for the pharmaceutical and biological processing industries has made a number of previously unknown companies from the People's Republic amazingly successful in a short period of time.

PROCESS regularly reports on the Chinese chemical and pharmaceutical market with the format 'China Market Insider'.(Source:  ©sezerozger - stock.adobe.com)
PROCESS regularly reports on the Chinese chemical and pharmaceutical market with the format 'China Market Insider'.
(Source: ©sezerozger - stock.adobe.com)

Beijing/China – A good indication of success is investor interest. When Suzhou Nanimicro Tech, a Chinese manufacturer of resins, went public on the STAR stock exchange in Shanghai in June this year, its shares rose 1273 % on the first day.

This particular niche had been considered ‘hot’ by investors even before the epidemic began because the bioprocessing market in China was growing rapidly even then. Wuxi Biologics, for example, acquired half of the shares of Bestchrome, another Chinese producer of resins, in late 2019. Since the epidemic began, however, the time has come for Chinese upstarts in the industry, such as ‘Bioscience,’ one of China’s largest producers of cell cultures. This Chinese contract development and manufacturing organization (CDMO) and producer of cell cultures, which already had a factory in Zhangjiang, could add cell culture capacity in Lingang, near Shanghai, in May 2020. The planned new annual capacity is in the range of several thousand tons and for liquid media, millions of liters, reports Bioprocess Online information service.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent